Detalhe da pesquisa
1.
Diffusion MRI marks progressive alterations in fiber integrity in the zQ175DN mouse model of Huntington's disease.
Neurobiol Dis
; 193: 106438, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365045
2.
Longitudinal alterations in brain perfusion and vascular reactivity in the zQ175DN mouse model of Huntington's disease.
J Biomed Sci
; 31(1): 37, 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627751
3.
Resting-state fMRI reveals longitudinal alterations in brain network connectivity in the zQ175DN mouse model of Huntington's disease.
Neurobiol Dis
; 181: 106095, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36963694
4.
Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin.
Eur J Nucl Med Mol Imaging
; 50(1): 48-60, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001116
5.
Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington's disease.
Eur J Nucl Med Mol Imaging
; 49(4): 1166-1175, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34651228
6.
Modelling the Human Blood-Brain Barrier in Huntington Disease.
Int J Mol Sci
; 23(14)2022 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35887162
7.
Kynurenine 3-Monooxygenase Inhibition during Acute Simian Immunodeficiency Virus Infection Lowers PD-1 Expression and Improves Post-Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight.
J Immunol
; 203(4): 899-910, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31285277
8.
Pharmacokinetics and metabolic disposition of a potent and selective kynurenine monooxygenase inhibitor, CHDI-340246, in laboratory animals.
Xenobiotica
; 51(10): 1155-1180, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496722
9.
Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtin.
Hum Mol Genet
; 27(13): 2330-2343, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29912367
10.
Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction.
Bioorg Med Chem
; 28(21): 115738, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33065433
11.
Application of an in Vitro Blood-Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington's Disease.
Mol Pharm
; 16(5): 2069-2082, 2019 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30916978
12.
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Bioorg Med Chem Lett
; 29(1): 83-88, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30463802
13.
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Arch Biochem Biophys
; 631: 31-41, 2017 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801166
14.
Support communities involved in disease studies.
Nature
; 531(7593): 141, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26961621
15.
Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease.
Mov Disord
; 29(11): 1397-403, 2014 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25155258
16.
Subtyping monogenic disorders: Huntington disease.
Handb Clin Neurol
; 193: 171-184, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36803810
17.
Longitudinal investigation of changes in resting-state co-activation patterns and their predictive ability in the zQ175 DN mouse model of Huntington's disease.
Sci Rep
; 13(1): 10194, 2023 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37353500
18.
In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using 11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease.
J Nucl Med
; 64(10): 1581-1587, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591545
19.
Design and Evaluation of [18F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates.
J Med Chem
; 66(1): 641-656, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36548390
20.
Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease.
J Med Chem
; 66(18): 13205-13246, 2023 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37712656